$2.59
3.00%
Nasdaq, Dec 26, 10:00 pm CET
ISIN
US09203E1055
Symbol
BDTX

Black Diamond Therapeutics Inc Stock price

$2.59
-1.19 31.48% 1M
+0.13 5.28% 6M
+0.45 21.03% YTD
+0.29 12.61% 1Y
+1.30 100.78% 3Y
-31.21 92.34% 5Y
-36.89 93.44% 10Y
-36.89 93.44% 20Y
Nasdaq, Closing price Fri, Dec 26 2025
-0.08 3.00%
ISIN
US09203E1055
Symbol
BDTX
Industry

Key metrics

Basic
Market capitalization
$147.6m
Enterprise Value
$12.1m
Net debt
positive
Cash
$135.5m
Shares outstanding
56.9m
Valuation (TTM | estimate)
P/E
7.0 | 5.4
P/S
2.1 | 2.1
EV/Sales
0.2 | 0.2
EV/FCF
0.6
P/B
1.2
Financial Health
Equity Ratio
67.9%
Return on Equity
-83.7%
ROCE
8.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$70.0m | $71.4m
EBITDA
$12.5m | $16.3m
EBIT
$12.1m | $17.4m
Net Income
$21.5m | $27.2m
Free Cash Flow
$21.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
115.4% | 120.8%
EBIT
115.0% | 122.0%
Net Income
129.2% | 139.1%
Free Cash Flow
135.1%
Margin (TTM | estimate)
Gross
-
EBITDA
17.8% | 22.9%
EBIT
17.3%
Net
30.7% | 38.1%
Free Cash Flow
30.6%
More
EPS
$0.4
FCF per Share
$0.4
Short interest
15.9%
Employees
24
Rev per Employee
$0.0
Show more

Is Black Diamond Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Black Diamond Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Black Diamond Therapeutics Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Black Diamond Therapeutics Inc forecast:

Buy
93%
Hold
7%

Financial data from Black Diamond Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
70 70
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
31% 31%
27%
- Research and Development Expense 40 40
27% 27%
57%
12 12
115% 115%
18%
- Depreciation and Amortization 0.34 0.34
3% 3%
0%
EBIT (Operating Income) EBIT 12 12
115% 115%
17%
Net Profit 21 21
129% 129%
31%

In millions USD.

Don't miss a Thing! We will send you all news about Black Diamond Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Black Diamond Therapeutics Inc Stock News

Neutral
GlobeNewsWire
26 days ago
CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced topline data from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with non-classical epidermal gro...
Neutral
GlobeNewsWire
27 days ago
Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a progra...
Positive
Seeking Alpha
about one month ago
Black Diamond Therapeutics remains undervalued despite recent share price gains, with a promising EGFR inhibitor pipeline targeting unmet needs. Silevertinib, BDTX's lead candidate, is advancing in NSCLC and glioblastoma, with key clinical updates expected in late 2025 and early 2026. BDTX's financial position is strong, with a cash runway extending into Q4 2027, supported by a recent $70 milli...
More Black Diamond Therapeutics Inc News

Company Profile

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Head office United States
CEO Mark Velleca
Employees 24
Founded 2014
Website www.blackdiamondtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today